---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000966"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T16:01:47.647572+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Celldex Q4 2023 net loss $43.3M; cash $423.6M; Phase 3 CSU study planned for summer 2024

## Summary
- Q4 2023 net loss $43.3M ($0.83/share) vs $26.5M ($0.56) in Q4 2022; FY net loss $141.4M ($2.92/share).
- Revenue $4.1M in Q4 2023 vs $1.6M in Q4 2022, primarily from Rockefeller University manufacturing agreements.
- Cash, cash equivalents and marketable securities $423.6M at Dec 31, 2023 vs $235.3M at Sep 30, 2023; $216.2M raised in Nov 2023 offering.
- Barzolvolimab: Positive Phase 2 CSU 12-week data; Phase 3 CSU studies expected to start summer 2024; 52-week data in 2H 2024.
- Phase 2 CIndU enrollment nearing completion (data 2H 2024); Phase 2 PN study to start early 2024; cash runway into 2026.

## SEC filing metadata
- accession: 0001171843-24-000966
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184324000966/0001171843-24-000966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184324000966/f8k_022524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000966
- JSON: https://secwatch.observer/filing/0001171843-24-000966.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000966.txt

## Key facts
- Earnings Releases
  Celldex Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 26, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000117184324000966/0001171843-24-000966-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.